연구성과로 돌아가기
2025 연구성과별 연구자 정보 (1123 / 1187)
※ 현재 Web of Science 저자 정보만 집계되어 있습니다.
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Document Title | Author Full Name | Author Short Name | Index | Corresponding | Address | ResearcherID | ResearcherID Author Name | ORCID | ORCID Author Name | Related Email |
|---|---|---|---|---|---|---|---|---|---|---|
| Transition toward Healthcare 5.0: Impact of COVID-19 in the healthcare industry | Raisa, Jasiya Fairiz | Raisa, JF | 1 | Bangladesh Univ Profess, Mirpur Cantonment, Dhaka 1216, Bangladesh | jasiyafairiz@gmail.com; sazzad@juniv.edu; imtiaztee@gmail.com; mskaiser@juniv.edu; dshan@knu.ac.kr; | |||||
| Transition toward Healthcare 5.0: Impact of COVID-19 in the healthcare industry | Rahman, Md. Sazzadur | Rahman, MS | 2 | 교신저자 | Jahangirnagar Univ, Inst Informat Technol, Savar 1342, Dhaka, Bangladesh | jasiyafairiz@gmail.com; sazzad@juniv.edu; imtiaztee@gmail.com; mskaiser@juniv.edu; dshan@knu.ac.kr; | ||||
| Transition toward Healthcare 5.0: Impact of COVID-19 in the healthcare industry | Mahmud, Imtiaz | Mahmud, I | 3 | Lawrence Berkeley Natl Lab, Berkeley, CA 94720, USA | R-1089-2019 | Mahmud, Imtiaz | jasiyafairiz@gmail.com; sazzad@juniv.edu; imtiaztee@gmail.com; mskaiser@juniv.edu; dshan@knu.ac.kr; | |||
| Transition toward Healthcare 5.0: Impact of COVID-19 in the healthcare industry | Kaiser, M. Shamim | Kaiser, MS | 4 | Jahangirnagar Univ, Inst Informat Technol, Savar 1342, Dhaka, Bangladesh | jasiyafairiz@gmail.com; sazzad@juniv.edu; imtiaztee@gmail.com; mskaiser@juniv.edu; dshan@knu.ac.kr; | |||||
| Transition toward Healthcare 5.0: Impact of COVID-19 in the healthcare industry | Han, Dong Seog | Han, DS | 5 | 교신저자 | Kyungpook Natl Univ, Sch Elect & Elect Engn, Daegu 41566, South Korea | jasiyafairiz@gmail.com; sazzad@juniv.edu; imtiaztee@gmail.com; mskaiser@juniv.edu; dshan@knu.ac.kr; | ||||
| Translation, Cultural Adaptation, and Validation of the Korean Version of the Multimorbidity Treatment Burden Questionnaire | Lee, Jihyang | Lee, JHY | 1 | Seoul Natl Univ, Coll Nursing, Seoul, South Korea | ellen92kr@snu.ac.kr; dain.park@knu.ac.kr; polly.duncan@bristol.ac.uk; kyounglee@snu.ac.kr; | |||||
| Translation, Cultural Adaptation, and Validation of the Korean Version of the Multimorbidity Treatment Burden Questionnaire | Park, Da-In | Park, D | 2 | Kyungpook Natl Univ, Res Inst Nursing Innovat, Coll Nursing, Daegu, South Korea | ellen92kr@snu.ac.kr; dain.park@knu.ac.kr; polly.duncan@bristol.ac.uk; kyounglee@snu.ac.kr; | |||||
| Translation, Cultural Adaptation, and Validation of the Korean Version of the Multimorbidity Treatment Burden Questionnaire | Duncan, Polly | Duncan, P | 3 | Univ Bristol, Ctr Acad Primary Care, Bristol, England | HHM-4052-2022 | Duncan, Polly | 0000-0002-2244-3254 | Duncan, Polly | ellen92kr@snu.ac.kr; dain.park@knu.ac.kr; polly.duncan@bristol.ac.uk; kyounglee@snu.ac.kr; | |
| Translation, Cultural Adaptation, and Validation of the Korean Version of the Multimorbidity Treatment Burden Questionnaire | Lee, Kyoung Suk | Lee, KS | 4 | 교신저자 | Seoul Natl Univ, Coll Nursing, Seoul, South Korea | ellen92kr@snu.ac.kr; dain.park@knu.ac.kr; polly.duncan@bristol.ac.uk; kyounglee@snu.ac.kr; | ||||
| Translation, Cultural Adaptation, and Validation of the Korean Version of the Multimorbidity Treatment Burden Questionnaire | Lee, Kyoung Suk | Lee, KS | 4 | 교신저자 | Seoul Natl Univ, Res Inst Nursing Sci, Coll Nursing, Seoul, South Korea | ellen92kr@snu.ac.kr; dain.park@knu.ac.kr; polly.duncan@bristol.ac.uk; kyounglee@snu.ac.kr; | ||||
| Trastuzumab deruxtecan (T-DXd) plus pertuzumab (P) vs taxane plus trastuzumab plus pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) advanced/metastatic breast cancer (a/mBC): Interim results from DESTINY-Breast09. | Tolaney, Sara M. | Tolaney, SM | 1 | AFZ-2612-2022 | Tolaney, S | |||||
| Trastuzumab deruxtecan (T-DXd) plus pertuzumab (P) vs taxane plus trastuzumab plus pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) advanced/metastatic breast cancer (a/mBC): Interim results from DESTINY-Breast09. | Jiang, Zefei | Jiang, ZF | 2 | |||||||
| Trastuzumab deruxtecan (T-DXd) plus pertuzumab (P) vs taxane plus trastuzumab plus pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) advanced/metastatic breast cancer (a/mBC): Interim results from DESTINY-Breast09. | Zhang, Qingyuan | Zhang, QY | 3 | |||||||
| Trastuzumab deruxtecan (T-DXd) plus pertuzumab (P) vs taxane plus trastuzumab plus pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) advanced/metastatic breast cancer (a/mBC): Interim results from DESTINY-Breast09. | Barroso-Sousa, Romualdo | Barroso-Sousa, R | 4 | T-6405-2019 | BARROSO-SOUSA, ROMUALDO | |||||
| Trastuzumab deruxtecan (T-DXd) plus pertuzumab (P) vs taxane plus trastuzumab plus pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) advanced/metastatic breast cancer (a/mBC): Interim results from DESTINY-Breast09. | Park, Yeon Hee | Park, YH | 5 |
페이지 이동: